Australia Health

Sigma Healthcare (ASX:SIG) reported a rise in financial performance for the half-year ended Dec. 31, 2025, driven by the integration of Chemist Warehouse and robust retail sales.

The Melbourne-based digital health firm Vitura Health (ASX:VIT) reported total revenue of $67.9 million for the half year to Dec. 31, 2025.

Imricor Medical Systems (ASX:IMR) announced its financial and operational results for the full year 2025.

EBOS Group (ASX:EBO) reported that underlying EBITDA rose by 3.2% to $300 million in the first half of fiscal 2026.

Radiopharm Theranostics (ASX:RAD) has commenced the first-in-human Phase 1/2a clinical trial of its novel radiopharmaceutical, 177Lu-Betabart (RV-01).

Integral Diagnostics (ASX:IDX) saw revenue and other income climb to $393.5 million in H1 FY26, a 55.6% increase a year ago.

Pharmx Technologies (ASX:PHX) entered into a binding, multi-year strategic alliance with Sigma Healthcare (ASX:SIG).

Biome (ASX:BIO) has delivered its performance for the first half of FY26, headlined by a net profit of $1.2 million, a 172% increase over the previous year.

Aged care giant Regis Healthcare (ASX:REG) reported a sharp 45.1% decline in statutory net profit for the first half of FY26, falling to $13.4 million.

Mayne Pharma (ASX:MYX) reported revenue of $212.1 million for the first half of FY26, a marginal 0.5% decrease compared to the previous corresponding period.

Fisher & Paykel Healthcare (ASX:FPH) has upgraded its revenue and earnings guidance for the 2026 financial year ending March 31.

Telix Pharmaceuticals (ASX:TLX) reported a financial performance for the fiscal year ended Dec. 31, 2025, characterised by a 56% rise in total revenue to US$803.8 million.